MedTrace Logo

Non-Coding RNAs Gene Expression in Psychiatric Disorders

NCT07649993 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 384

Last updated 2026-06-23

No results posted yet for this study

Summary

This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, panic disorder, and obsessive-compulsive disorder. Researchers will compare the expression levels of these molecules in patients who are drug-naïve or have been free from psychiatric treatment for at least six months with those observed in healthy volunteers.

The study will also evaluate whether the expression of these non-coding RNAs changes after approximately five months of standard psychiatric treatment. Blood samples collected during routine clinical care will be used to measure the expression levels of selected non-coding RNAs using reverse transcription quantitative polymerase chain reaction (RT-qPCR), a laboratory technique used to assess gene expression.

This is an observational study and does not assign specific treatments. All therapies will be prescribed according to standard clinical practice.

The main objective is to determine whether alterations in non-coding RNA expression may serve as biological markers of psychiatric disorders and whether these markers may help monitor treatment-related changes over time. The findings may contribute to a better understanding of the biological mechanisms underlying major psychiatric disorders and support the future development of more accurate diagnostic and therapeutic approaches.

Conditions

  • Schizophrenia Disorders
  • Major Depression
  • Bipolar Affective Disorders
  • Obsessive Compulsive Disorder (OCD)
  • Anxiety Disorder (Panic Disorder or GAD)

Interventions

GENETIC

Reverse Transcription Quantitative Polymerase Chain Reaction

Gene expression analysis of selected non-coding RNAs using reverse transcription quantitative polymerase chain reaction (RT-qPCR).

Sponsors & Collaborators

  • Carmen Concerto

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-09-01
Completion
2028-09-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07649993 on ClinicalTrials.gov